Adult-Onset Fluoxetine Treatment Does Not Improve Behavioral Impairments and May Have Adverse Effects on the Ts65Dn Mouse Model of Down Syndrome

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left"></td><td align="center">2N</td><td align="center">Ts65Dn</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Vehicle</td><td align="center">0 (0%)</td><td align="center">0 (0%)</td></tr><tr><td align="left">Fluoxetine</td><td align="center">0 (0%)</td><td align="center">3 (33.3%)</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Number of animals displaying seizures stratified by genotype and treatment group.

Neural Plasticity

tab2

Table 2

Table 2: Adult-Onset Fluoxetine Treatment Does Not Improve Behavioral Impairments and May Have Adverse Effects on the Ts65Dn Mouse Model of Down Syndrome 

Table 2 | Adult-Onset Fluoxetine Treatment Does Not Improve Behavioral Impairments and May Have Adverse Effects on the Ts65Dn Mouse Model of Down Syndrome 